Botulinum toxin type a for the treatment of the upper limb spasticity after stroke: A meta-analysis

Arquivos de Neuro-Psiquiatria

Volumn 63, Issue 1, 2005, Pages 30-33

  Cardoso, Eduardo ^a   Rodrigues, Bernardo ^a   Lucena, Rita ^a   Reis De Oliveira, Irismar ^a   Pedreira, Glícia ^a   Melo, Ailton ^a,b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b NONE   (Brazil)

Author keywords

Botulinum toxin; Rehabilitation; Spasticity; Stroke

Indexed keywords

BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN A; PHENOL; PLACEBO; TIZANIDINE;

ARM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; META ANALYSIS; MODIFIED ASHWORTH SCALE; PAIN; PHYSIOTHERAPY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPASTICITY; STATISTICAL ANALYSIS; STROKE; SYSTEMATIC REVIEW;

EID: 17444387942     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0004-282X2005000100006     Document Type: Article

References (14)

1. Nakaiama H, Jorgensen HS, Raaschou HO, et al. Recovery of upper extremity function in stroke patients: the Copenhagen stroke study. Arch Phys Med Rehab 1994;75:394-398.
2. Rousseaux M, Kozlowski O, Froger J. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients. J Neurol 2002;249:76-84
3. Wade DT. Physiotherapy intervention late after stroke and morbidity. BMJ 1992;304:609-613.
4. Mizrahi EM, Angel RW. Impairment of voluntary movement by spasricity. Ann Neurol. 1979;5:494-495.
5. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993;365:160-163.
6. Jadad AR, Moore A, Carrol D. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
7. Bohannom RW, Smith MB. Inter-rater reliability of a modified Ashworth Scale of muscle spasticity. Phys Ther. 1987;67:206-207.
8. Bhakta BB, Cozens JA, Chamberlian MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randonised double blind placebo controlled trial. J Neurol Neurosurg Psychiartry 2001;70:821.
9. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomised, double-blind, placebo-controlled trial. Neurology 1996;46:1306-1310.
10. Smith SJ, Ellis E, White S, Moore AP. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000;14:5-13.
11. Bakheit AM, Thilmann AF, Ward AB, et al. A randomised, double-blind, placebo-controlled, dose-raging study to compare the efficacy and safety of three doses of botulinum toxin type A with placebo in upper limb spasticity after stroke. Stroke 2000;31:2402-2406.
12. Bakheit AMO, Pittock S, Moore AP, et al. A randomised, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001;8:559-565.
13. Brashear A, Gordon MF, Elovic E, et al. Intra-muscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002;347:395-400.
14. Bakheit AMO. Optimising the methods of evaluation of the effectiveness of botuilinum toxin treatment of post-stroke muscle spasticity. J Neurol Neurosurg Psychiatry 2004;75:665-666.